{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:37:03Z","timestamp":1789843023365,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,11]]},"DOI":"10.7759\/cureus.45044","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T15:09:48Z","timestamp":1694444988000},"source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Uses of Rituximab and Clinical Features in Immunoglobulin G4-Related Disease: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Utkarsh","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayushi","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhara","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismat E","family":"Ayesha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neetha R","family":"Monson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimra","family":"Klair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Kashmer","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2023.2195627","article-title":"IgG4-related disease: advances in pathophysiology and treatment","volume":"19","author":"Peyronel F","year":"2023","unstructured":"Peyronel F, Fenaroli P, Maritati F, Schleinitz N, Vaglio A. IgG4-related disease: advances in pathophysiology and treatment. Expert Rev Clin Immunol. 2023, 19:537-47. 10.1080\/1744666X.2023.2195627","journal-title":"Expert Rev Clin Immunol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06413-7","article-title":"Roles of IgG4 and IgG4\/IgG ratio to IgG4-related disease in patients with elevated serum IgG4 level","volume":"42","author":"Wang H","year":"2023","unstructured":"Wang H, Wang C, Wan Q, Li L. Roles of IgG4 and IgG4\/IgG ratio to IgG4-related disease in patients with elevated serum IgG4 level. Clin Rheumatol. 2023, 42:793-800. 10.1007\/s10067-022-06413-7","journal-title":"Clin Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2020.100047","article-title":"Immunological mechanism of IgG4-related disease","volume":"3","author":"Liu C","year":"2020","unstructured":"Liu C, Zhang P, Zhang W. Immunological mechanism of IgG4-related disease. J Transl Autoimmun. 2020, 3:100047. 10.1016\/j.jtauto.2020.100047","journal-title":"J Transl Autoimmun"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1148\/rg.220097","article-title":"Anatomic and functional imaging of immunoglobulin G4-related disease and its mimics","volume":"43","author":"Huynh KN","year":"2023","unstructured":"Huynh KN, Kong MJ, Nguyen BD. Anatomic and functional imaging of immunoglobulin G4-related disease and its mimics. Radiographics. 2023, 43:e220097. 10.1148\/rg.220097","journal-title":"Radiographics"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-23488-0_50","article-title":"IgG4-related disease","author":"Kawano M","year":"2023","unstructured":"Kawano M, Zen Y, Saeki T, et al.. IgG4-related disease. A Clinician's Pearls & Myths in Rheumatology. Stone JH (ed): Springer, Cham, Switzerland; 2023. 701-25. 10.1007\/978-3-031-23488-0_50"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-023-09771-3","article-title":"Inflammatory and infectious disorders in endocrine pathology","author":"Uccella S","year":"2023","unstructured":"Uccella S, Dottermusch M, Erickson L, Warmbier J, Montone K, Saeger W. Inflammatory and infectious disorders in endocrine pathology. Endocr Pathol. 2023, 1-31. 10.1007\/s12022-023-09771-3","journal-title":"Endocr Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-323-98818-6.00008-X","article-title":"Adult and childhood vasculitis","volume":"195","author":"Younger DS","year":"2023","unstructured":"Younger DS. Adult and childhood vasculitis. Handb Clin Neurol. 2023, 195:653-705. 10.1016\/B978-0-323-98818-6.00008-X","journal-title":"Handb Clin Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40734","article-title":"Rituximab in pemphigus vulgaris: a review of monoclonal antibody therapy in dermatology","volume":"15","author":"Khandelwal K","year":"2023","unstructured":"Khandelwal K, Jajoo V, Bajpai K, et al.. Rituximab in pemphigus vulgaris: a review of monoclonal antibody therapy in dermatology. Cureus. 2023, 15:e40734. 10.7759\/cureus.40734","journal-title":"Cureus"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0247067","article-title":"Small-sided games: an umbrella review of systematic reviews and meta-analyses","volume":"16","author":"Clemente FM","year":"2021","unstructured":"Clemente FM, Afonso J, Sarmento H. Small-sided games: an umbrella review of systematic reviews and meta-analyses. PLoS One. 2021, 16:e0247067. 10.1371\/journal.pone.0247067","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge C","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019, 4:5. 10.1186\/s41073-019-0064-8","journal-title":"Res Integr Peer Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea BJ","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al.. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017, 358:j4008. 10.1136\/bmj.j4008","journal-title":"BMJ"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.11124\/JBISRIR-D-19-00099","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn Z","year":"2020","unstructured":"Munn Z, Barker TH, Moola S, et al.. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synth. 2020, 18:2127-33. 10.11124\/JBISRIR-D-19-00099","journal-title":"JBI Evid Synth"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1354698","article-title":"Diagnostic and treatment workup for IgG4-related disease","volume":"13","author":"Abraham M","year":"2017","unstructured":"Abraham M, Khosroshahi A. Diagnostic and treatment workup for IgG4-related disease. Expert Rev Clin Immunol. 2017, 13:867-75. 10.1080\/1744666X.2017.1354698","journal-title":"Expert Rev Clin Immunol"},{"key":"ref16","article-title":"IgG-4 related disease: an introduction","volume":"115","author":"Al-Khalili OM","year":"2018","unstructured":"Al-Khalili OM, Erickson AR. IgG-4 related disease: an introduction. Mo Med. 2018, 115:253-6.","journal-title":"Mo Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2018.20","article-title":"Immunoglobulin G4-related disease: an update","volume":"33","author":"Al-Mujaini A","year":"2018","unstructured":"Al-Mujaini A, Al-Khabori M, Shenoy K, Wali U. Immunoglobulin G4-related disease: an update. Oman Med J. 2018, 33:97-103. 10.5001\/omj.2018.20","journal-title":"Oman Med J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001891","article-title":"Update on classification, diagnosis, and management of immunoglobulin G4-related disease","volume":"135","author":"Chen Y","year":"2022","unstructured":"Chen Y, Cai S, Dong L, Umehara H. Update on classification, diagnosis, and management of immunoglobulin G4-related disease. Chin Med J (Engl). 2022, 135:381-92. 10.1097\/CM9.0000000000001891","journal-title":"Chin Med J (Engl)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.39205","article-title":"IGG4-related disease: clinical and laboratory features in one hundred twenty-five patients","volume":"67","author":"Wallace ZS","year":"2015","unstructured":"Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH. IGG4-related disease: clinical and laboratory features in one hundred twenty-five patients. Arthritis Rheumatol. 2015, 67:2466-75. 10.1002\/art.39205","journal-title":"Arthritis Rheumatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.9399.1","article-title":"Recent advances in understanding and managing IgG4-related disease","volume":"6","author":"Wolfson AR","year":"2017","unstructured":"Wolfson AR, Hamilos DL. Recent advances in understanding and managing IgG4-related disease. F1000Res. 2017, 6:10.12688\/f1000research.9399.1","journal-title":"F1000Res"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2021.1886630","article-title":"B cell targeted therapy for immunoglobulin G4-related disease","volume":"44","author":"Yamamoto M","year":"2021","unstructured":"Yamamoto M. B cell targeted therapy for immunoglobulin G4-related disease. Immunol Med. 2021, 44:216-22. 10.1080\/25785826.2021.1886630","journal-title":"Immunol Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2016.07.003","article-title":"IgG4-related disease: advances in the diagnosis and treatment","volume":"30","author":"Brito-Zer\u00f3n P","year":"2016","unstructured":"Brito-Zer\u00f3n P, Bosch X, Ramos-Casals M, Stone JH. IgG4-related disease: advances in the diagnosis and treatment. Best Pract Res Clin Rheumatol. 2016, 30:261-78. 10.1016\/j.berh.2016.07.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004002","article-title":"Therapeutic approach to IgG4-related disease: a systematic review","volume":"95","author":"Brito-Zer\u00f3n P","year":"2016","unstructured":"Brito-Zer\u00f3n P, Kostov B, Bosch X, Acar-Denizli N, Ramos-Casals M, Stone JH. Therapeutic approach to IgG4-related disease: a systematic review. Medicine (Baltimore). 2016, 95:e4002. 10.1097\/MD.0000000000004002","journal-title":"Medicine (Baltimore)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi C","year":"2019","unstructured":"Kaegi C, Wuest B, Schreiner J, et al.. Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol. 2019, 10:1990. 10.3389\/fimmu.2019.01990","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2018.11.011","article-title":"IgG4-related disease: is rituximab the best therapeutic strategy for cases refractory to conventional therapy? Results of a systematic review","volume":"16","author":"Betancur-V\u00e1squez L","year":"2020","unstructured":"Betancur-V\u00e1squez L, Gonzalez-Hurtado D, Arango-Isaza D, Rojas-Villarraga A, Hernandez-Parra D, Carmona S, D\u00edaz-Coronado JC. IgG4-related disease: is rituximab the best therapeutic strategy for cases refractory to conventional therapy? Results of a systematic review. Reumatol Clin (Engl Ed). 2020, 16:195-202. 10.1016\/j.reuma.2018.11.011","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez380","article-title":"Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis","volume":"59","author":"Omar D","year":"2020","unstructured":"Omar D, Chen Y, Cong Y, Dong L. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology (Oxford). 2020, 59:718-26. 10.1093\/rheumatology\/kez380","journal-title":"Rheumatology (Oxford)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282852","article-title":"Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease","volume":"18","author":"Choi SJ","year":"2023","unstructured":"Choi SJ, Ahn SM, Oh JS, Hong S, Lee CK, Yoo B, Kim YG. Serum IgG4 level during initial treatment as a predictor of relapse in IgG4-related disease. PLoS One. 2023, 18:e0282852. 10.1371\/journal.pone.0282852","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab","volume":"55","author":"Wallace ZS","year":"2016","unstructured":"Wallace ZS, Mattoo H, Mahajan VS, et al.. Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford). 2016, 55:1000-8. 10.1093\/rheumatology\/kev438","journal-title":"Rheumatology (Oxford)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1567-2","article-title":"Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients","volume":"20","author":"Wang L","year":"2018","unstructured":"Wang L, Zhang P, Wang M, et al.. Failure of remission induction by glucocorticoids alone or in combination with immunosuppressive agents in IgG4-related disease: a prospective study of 215 patients. Arthritis Res Ther. 2018, 20:65. 10.1186\/s13075-018-1567-2","journal-title":"Arthritis Res Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1177\/20406223211028776","article-title":"Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry","volume":"12","author":"Zongfei J","year":"2021","unstructured":"Zongfei J, Lijuan Z, Ying S, et al.. Improved clinical outcomes of tocilizumab versus cyclophosphamide for IgG4-related disease: insights from a prospective IgG4-related disease registry. Ther Adv Chronic Dis. 2021, 12:10.1177\/20406223211028776","journal-title":"Ther Adv Chronic Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v7.i16.2309","article-title":"Successful treatment of tubulointerstitial nephritis in immunoglobulin G4-related disease with rituximab: a case report","volume":"7","author":"Eroglu E","year":"2019","unstructured":"Eroglu E, Sipahioglu MH, Senel S, et al.. Successful treatment of tubulointerstitial nephritis in immunoglobulin G4-related disease with rituximab: a case report. World J Clin Cases. 2019, 7:2309-15. 10.12998\/wjcc.v7.i16.2309","journal-title":"World J Clin Cases"},{"key":"ref32","article-title":"Successful treatment of IgG-4 related sclerosing disease with rituximab: a novel case report","volume":"33","author":"Gillispie MC","year":"2015","unstructured":"Gillispie MC, Thomas RD, Hennon TR. Successful treatment of IgG-4 related sclerosing disease with rituximab: a novel case report. Clin Exp Rheumatol. 2015, 33:549-50.","journal-title":"Clin Exp Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12100","article-title":"IgG4-related disease with cutaneous manifestations treated with rituximab: case report and literature review","volume":"55","author":"Jalilian C","year":"2014","unstructured":"Jalilian C, Prince HM, McCormack C, Lade S, Cheah CY. IgG4-related disease with cutaneous manifestations treated with rituximab: case report and literature review. Australas J Dermatol. 2014, 55:132-6. 10.1111\/ajd.12100","journal-title":"Australas J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2017-001826","article-title":"Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases","volume":"18","author":"Mageau A","year":"2018","unstructured":"Mageau A, Shor N, Fisselier M, et al.. Rituximab for corticosteroid-resistant relapsing IgG4-related intracranial pachymeningitis: report of two cases. Pract Neurol. 2018, 18:159-61. 10.1136\/practneurol-2017-001826","journal-title":"Pract Neurol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04787-x","article-title":"Two cases of refractory IgG4-related disease successfully treated with tocilizumab","volume":"101","author":"Ong J","year":"2022","unstructured":"Ong J, Brown S, Gilbertson M, et al.. Two cases of refractory IgG4-related disease successfully treated with tocilizumab. Ann Hematol. 2022, 101:1593-4. 10.1007\/s00277-022-04787-x","journal-title":"Ann Hematol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216368","article-title":"Dupilumab as a novel steroid-sparing treatment for IgG4-related disease","volume":"79","author":"Simpson RS","year":"2020","unstructured":"Simpson RS, Lau SK, Lee JK. Dupilumab as a novel steroid-sparing treatment for IgG4-related disease. Ann Rheum Dis. 2020, 79:549-50. 10.1136\/annrheumdis-2019-216368","journal-title":"Ann Rheum Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13430","article-title":"Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review","volume":"47","author":"Wang Y","year":"2017","unstructured":"Wang Y, Li K, Gao D, et al.. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: a retrospective study and literature review. Intern Med J. 2017, 47:680-9. 10.1111\/imj.13430","journal-title":"Intern Med J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.83368","article-title":"IgG4-related disease and the spectrum of mimics in rheumatology","author":"Sebastian A","year":"2019","unstructured":"Sebastian A, Donizy P, Wiland P. IgG4-related disease and the spectrum of mimics in rheumatology. Chronic Autoimmune Epithelitis - Sjogren's Syndrome and Other Autoimmune Diseases of the Exocrine Glands. Ma\u015bli\u0144ska M (ed): IntechOpen, London, UK; 2019. 10.5772\/intechopen.83368"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/184596-therapeutic-uses-of-rituximab-and-clinical-features-in-immunoglobulin-g4-related-disease-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:29Z","timestamp":1707509189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/184596-therapeutic-uses-of-rituximab-and-clinical-features-in-immunoglobulin-g4-related-disease-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.45044","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,11]]}}}